MedTrace Logo

Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab

NCT01927757 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-01-30

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.

Conditions

  • Moderate to Severe Rheumatoid Arthritis

Interventions

BIOLOGICAL

Etanercept

Administered by subcutaneous injection

DRUG

Methotrexate

Background methotrexate at least 15 mg weekly

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-06
Primary Completion
2015-06-11
Completion
2015-06-11

Countries

  • United States
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01927757 on ClinicalTrials.gov